KR101045867B1 - Antifungal and antibacterial combination cleaning composition - Google Patents

Antifungal and antibacterial combination cleaning composition Download PDF

Info

Publication number
KR101045867B1
KR101045867B1 KR1020057003311A KR20057003311A KR101045867B1 KR 101045867 B1 KR101045867 B1 KR 101045867B1 KR 1020057003311 A KR1020057003311 A KR 1020057003311A KR 20057003311 A KR20057003311 A KR 20057003311A KR 101045867 B1 KR101045867 B1 KR 101045867B1
Authority
KR
South Korea
Prior art keywords
antifungal
cleaning composition
antibacterial
agent
soap
Prior art date
Application number
KR1020057003311A
Other languages
Korean (ko)
Other versions
KR20050059141A (en
Inventor
시게노부 키츠기
노리유키 코마츠
Original Assignee
모치다 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모치다 세이야쿠 가부시키가이샤 filed Critical 모치다 세이야쿠 가부시키가이샤
Publication of KR20050059141A publication Critical patent/KR20050059141A/en
Application granted granted Critical
Publication of KR101045867B1 publication Critical patent/KR101045867B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Abstract

본 발명은 넓은 항세균, 항진균 스펙트럼을 갖는, 유효성 및 안정성이 우수한 의약품, 의약부외품 또는 화장용품의 세정용 조성물을 제공한다. 아졸계 항진균제 및 항세균제가 배합된 의약품, 의약부외품 또는 화장용품의 세정용 조성물을 제공한다. 상기 아졸계 항진균제로서는 질산 미코나졸이 특히 바람직하다.

Figure R1020057003311

The present invention provides a cleaning composition for medicines, quasi-drugs, or cosmetics having a wide range of antibacterial and antifungal spectra and excellent efficacy and stability. Provided are cleaning compositions for medicines, quasi-drugs, or cosmetics containing azole antifungal agents and antibacterial agents. As said azole antifungal agent, myconazole nitrate is especially preferable.

Figure R1020057003311

Description

항진균제 및 항세균제 배합 세정용 조성물{CLEANSING COMPOSITION CONTAINING ANTIFUNGAL AGENT AND ANTIBACTERIAL AGENT}CLEANSING COMPOSITION CONTAINING ANTIFUNGAL AGENT AND ANTIBACTERIAL AGENT}

본 발명은 넓은 항세균, 항진균 스펙트럼을 갖는, 유효성 및 안정성이 우수한 의약품, 의약부외품 또는 화장용품의 세정용 조성물에 관한 것이다. The present invention relates to a cleaning composition for medicines, quasi-drugs, or cosmetics having a broad antibacterial and antifungal spectrum and excellent efficacy and stability.

일상적인 손세척의 가장 일반적인 방법은 비누와 흐르는 물에 의한 것으로, 이것은 손에 부착된 더러운 것, 유기물, 일과성 미생물(세균, 진균, 바이러스 등)의 물리적 제거법이다. 이와 같은 손세척에 의한 제균효과를 조사하기 위한 실험에서는 인위적으로 손에 부착시킨 균의 제균효과는 손세척 시간에 의존하고, 균량은 손세척 시간 15초로 1/10, 30초로 1/100, 1분 이상으로 1/1000이 된다고 보고되었다. 즉, 통상의 비누와 흐르는 물에 의해 1분 이상 세정하면, 부착된 균을 충분하게 제거할 수 있다. 그러나, 통상 손세척에 있어, 1분 이상의 손세척 시간을 확보하는 것은 몹시 어렵다. The most common method of daily hand washing is with soap and running water, which is the physical removal of dirt, organics, and transient microorganisms (bacteria, fungi, viruses, etc.) attached to the hands. In the experiment for investigating the bactericidal effect by hand washing, the bactericidal effect of the bacteria attached to the hand was dependent on the hand washing time, and the amount of bacteria was 1/10, 15 seconds for hand washing time, 1/100, 1 for 30 seconds. It has been reported to be 1/1000 in minutes or more. That is, if it wash | cleans with normal soap and running water for 1 minute or more, the adherent microbe can fully be removed. However, in hand washing, it is very difficult to secure a hand washing time of more than one minute.

그래서, 세정시의 제균효과를 높이기 위해 항세균제 배합 비누가 시판되고 있다. 식중독의 예방, 토양 또는 애완동물 등으로부터 부착된 환경유래의 세균의 살균소독, 원내감염방지 등을 위해서, 특히 균감염이 중요시되는 식품제조, 의료현장 등의 종사자에 사용되고 있는 것 만은 아니고, 일반가정에서의 항세균제 배합 비누로 세정은 일상적으로 되고 있다. Therefore, antibacterial compounded soaps are commercially available to enhance the bactericidal effect at the time of washing. In order to prevent food poisoning, sterilization and disinfection of environmentally-derived bacteria from soil or pets, and to prevent internal infections, it is not only used in food manufacturing, medical field, etc. Cleaning with antibacterial soaps in Japan has become routine.

이와 같은 항세균 배합 비누로서, 트리클로산, 트리클로칼반 및/또는 이소프로필메틸페놀 등의 항세균제를 포함하는 항세균제 배합 비누가 시판되고 있다. As such antibacterial compounding soaps, antibacterial compounding soaps containing antibacterial agents such as triclosan, triclocarban and / or isopropylmethylphenol are commercially available.

또한 비듬방지를 위한 항진균제를 배합한 조성물이 수개 알려져 있다. In addition, several compositions containing antifungal agents for preventing dandruff are known.

진균 P. ovale에 대해, 강력한 항진균 효과를 나타내는 미코나졸 또는 그의 질산염(nitrate)을 포함하는 비듬방지제가 개시되어 있다(일본 특허공개 평8-3042호 공보). 여기에서의 방지제는 P. ovale 에 의한 비듬을 방지하기 위한 예컨대, 샴프 등이고, 상기 방지제에는 상술한 것과 같은 항세균제는 배합되어 있지 않다. For fungal P. ovale , an anti-dandruff agent comprising myconazole or nitrate thereof that exhibits strong antifungal effect is disclosed (Japanese Patent Laid-Open No. 8-3042). The inhibitor herein is, for example, a shampoo or the like for preventing dandruff caused by P. ovale , and the antibacterial agent as described above is not incorporated in the inhibitor.

균, 곰팡이의 에르고스테롤의 생합성을 저해하는 1종 이상의 세균, 항곰팡이제와 인지질을 함유하는 조성물을 개시한 것도 있다(일본 특허 공개 2001-519822호 공부). 상기 문헌에서는 항균, 항곰팡이제로서 항진균제인 아졸이 개시되고 항세균제로서 공지의 화합물은 예시되어 있지 않다. 피부계상균(dermatophy te fungi)에 대하여 효과를 갖는 취지의 기재로부터 보아도, 상기 문헌에 있어서는 균은 실질적으로 진균을 의미하고, 항세균제는 포함되지 않는다. There is also disclosed a composition containing one or more bacteria, antifungal agents and phospholipids that inhibit the biosynthesis of bacteria and fungi ergosterol (Japanese Patent Laid-Open No. 2001-519822). In this document, azole, an antifungal agent, is disclosed as an antibacterial and antifungal agent, and a known compound is not exemplified as an antibacterial agent. Even from the description of the effect on dermatophyte fungi, in this document, the bacteria substantially mean fungi, and no antibacterial agent is included.

특정 계면활성제와 함께 활성제로서 항지루성 활성제 및/또는 항균제를 포함하는 지성 또는 여드름 경향의 피부를 위한 기포성 클린싱 크림을 개시하고 있는 것이 있다.(일본 특허공개 2002-145736호 공보). 상기 문헌에는 상기 항균제의 예시 군중에는 항생물질와 함께 항진균제인 미코나졸 및 그의 염산염 등도 개시되어 있다. 항균제는 2종 이상 사용하여도 좋다고 기재되고 있지만, 항균제를 2종 이상 포함할 필요성은 각별하게 나타나 있지 않다. There is disclosed a foaming cleansing cream for oily or acne-prone skin comprising an anti-seborrheic active agent and / or an antimicrobial agent as an active agent together with a specific surfactant (Japanese Patent Laid-Open No. 2002-145736). The document also discloses the antifungal agent myconazole and its hydrochloride salt, together with antibiotics in the exemplary population of the antimicrobial agent. Although it is described that you may use 2 or more types of antibacterial agents, the necessity to include 2 or more types of antibacterial agents does not show specially.

살균제와 수팽윤성 점도 광물과의 복합체를 포함하는 피부보호효과의 살균제 조성물도 제안되어 있다(일본특허 공개 평 10-265408호 공부). 상기 문헌중에는 살균제로서 트리클로산, 이소프로필메틸페닐 등의 항세균제, 아졸계 항진균제 등이 기재되어 있다. 또한 상기 문헌에는 살균제를 상기 점도 광물과의 복합체로 하여 사용하면, 항균력의 지속성이 있고 살균제는 임의로 1종 또는 2종 이상이 선택될 수 있는 취지가 기재되어 있지만, 각 용도별로 예시된 실시예에서는 각 용도에 따른 1종의 약제를 상기 점도 광물과의 복합체로 형성할 때의 지속성 효과를 나타내고 있다. A fungicide composition having a skin protective effect including a complex of a fungicide and a water-swellable viscosity mineral has also been proposed (Japanese Patent Laid-Open No. 10-265408). In this document, antibacterial agents such as triclosan and isopropylmethylphenyl, azole antifungal agents and the like are described as fungicides. In addition, the literature describes that when a fungicide is used as a complex with the viscosity mineral, the antimicrobial activity is sustained and one or two or more fungicides may be arbitrarily selected. The sustaining effect at the time of forming one type of chemical | medical agent according to each use into the complex with the said viscosity mineral is shown.

상기 각각의 문헌에는 항세균제와 항진균제를 조합시켜 사용할 필요는 나타나 있지 않다. In each of these documents, there is no need to use a combination of antibacterial and antifungal agents.

인간의 피부에는 통상, 다수의 상존 균이나 통과 균이 존재한다. 예컨대, S. aureus는 피부감염증의 가장 빈도가 높은 원인세균이고, 일상적으로 볼수 있는 질환으로는 수포성 농가진 등이 있다. 또한 T. rubrum 이나 T. mentagrophytes는 피부사상균증(백선)의 원인진균이다. 족백선(무좀)은 위중한 예를 제외하고 자각증상이 약하며, 타인에 감염되는 전염병인 것으로 인식은 충분하지 않고, 자각증상이 없게 되어 치료를 중단하고 말기 때문에(컴플라이언스가 안좋음), 목욕탕 내의 매트나 슬리퍼 등으로부터 감염될 기회가 많다. 숙주에 따라 통과하는 균량이 적어도 무좀을 발병한다는 보고가 있다. Human skin usually contains a large number of existing bacteria or passing bacteria. For example, S. aureus is the most frequent causative agent of skin infections, and commonly seen diseases include bullous impetigo. T. rubrum or T. mentagrophytes are also the causative agents of dermatophytosis (ringworm). Except for the above mentioned cases, the pedigerous pedigree is weak in awareness, is not enough to be recognized as an infectious disease infected by other people, and there is no awareness of symptoms, so the treatment is stopped (compliance is not good). There are many chances of getting infected from slippers. Depending on the host, it is reported that the amount of bacteria passing through causes at least athlete's foot.

또한 피부질환뿐만 아니라, 손에 부착된 진균이 경구적으로 체내에 투입되어, 각종 장기에서 진균감염증을 발증할 수도 있다. In addition, as well as skin diseases, fungi attached to the hand may be orally injected into the body, and fungal infections may develop in various organs.

또한 진균(곰팡이)는 알레르기성 감염의 원인(알레르겐)의 하나가 되어, 알레르기성 피부질환으로서 아토피성 피부염에 관련되고, 칸디다(C. albicans)가 중요시되고 있다. In addition, fungi (fungus) become one of the causes of allergic infections (allergens), and are associated with atopic dermatitis as an allergic skin disease, and Candida ( C. albicans ) is considered important.

최근, 생활환경의 변화, 항균물질, 스테로이드제 등의 약제의 일상적인 사용 등에 의해, 감염증에 대한 저항성은 저하되는 경향이라고 하지만, 숙주의 감염기능의 저하에 의해 발증하는 기회감염도 문제시되고 있다. 기회감염의 예방의 관점에서는 피부의 세정에 의해 감염예방하는 것은 세균만이 아니고 진균 제거의 필요성도 중요시되기 시작되고 있다. In recent years, resistance to infectious diseases tends to be lowered due to changes in the living environment, daily use of drugs such as antimicrobial substances, steroids, etc., but opportunistic infections caused by lowering the infectious function of the host are also a problem. In view of the prevention of opportunistic infections, the prevention of infection by cleaning the skin is not only about bacteria, but also the need for fungal removal is beginning to be important.

그러나, 상기 종래의 항세균제 배합 비누의 항진균효과를 조사하면, 상기 T. rubrum 등의 항진균 효과는 거의 없고, 불충분한 것을 알았다. 이들 항세균제 배합 비누는 식중독의 예방, 환경유래의 세균의 살균소독 등을 주로 목적으로 하기 때문에, 대장균, 살모넬라균, 포도구균 등의 세균의 살균, 감염 등의 항세균효과를 목적으로 하고, 특히 피부에 부착된 진균의 항진균효과는 어느 정도 중요시되고 있다고는 말할 수 없는 상태이다. However, when the antifungal effect of the conventional antibacterial agent-containing soap was examined, it was found that the antifungal effect of T. rubrum and the like was little and insufficient. Since these antibacterial soaps are mainly intended for the prevention of food poisoning and disinfection of environmentally-derived bacteria, they are aimed at antibacterial effects such as sterilization and infection of bacteria such as Escherichia coli, Salmonella and Staphylococcus aureus. In particular, the antifungal effect of the fungi attached to the skin can not be said to some extent important.

상기와 같은 상태를 보고, 본 발명자들은 넓은 항세균, 항진균 스펙트럼을 갖는 세정용 조성물의 필요성을 확인하였다. Looking at the above state, the present inventors have identified the need for a cleaning composition having a broad antibacterial, antifungal spectrum.

본 발명자는 이의 확인에 기초하여 항진균제 및 항세균제를 배합한 세정용 조성물에 관한 각종 검토과정에 있어, 항진균제중에서는 이들을 통상의 항세균성 비누에 그대로 배합해서도 그 용해성, 효과, 안정성 등이 크게 변화해 버리고, 안정한 세정용 조성물을 얻기가 곤란하다는 과제가 있다는 것을 알았다. The inventors of the present invention have conducted various studies on cleaning compositions in which antifungal agents and antibacterial agents are combined on the basis of the confirmation thereof. It turned out, and it turned out that there exists a subject that it is difficult to obtain a stable cleaning composition.

또한 항진균제, 항세균제 및 세정성분중에서는 피부자극작용을 갖는 것이 있기 때문에, 그 조합이나 배합량의 조절에 의해 효과(항진균효과, 항세균효과, 세정효과, 항세균제·항진균제의 잔류효과등)과 안전성(피부자극성이 적음 등)과의 발란스를 도모하는 것이 필요하다. In addition, some antifungal agents, antibacterial agents, and cleaning ingredients have skin irritation effects, and thus, by controlling the combination and the amount of the combination, the effect is antifungal, antibacterial, cleansing, and residual effects of antibacterial and antifungal agents. It is necessary to aim for balance between safety and safety (less skin irritation).

본 발명은 이들의 과제를 해결하기 위해, 항진균제 및 항세균제를 배합한 세정용 조성물, 특히 의약품, 의약부외품 또는 화장용품으로서 사용하려는 세정용 조성물에 있어서, 강력하고 넓은 항세균, 항진균 스펙트럼을 갖고, 안정하고 사용감이 우수하고, 세정력이 우수하며, 피부자극성이 적고, 두피나 신체의 가려움의 방지나 방취효과를 얻을 수 있고, 상주균이나 통과균에 의한 감염증의 예방효과를 얻을 수 있는 세정용 조성물을 제공하는 것을 목적으로 한다. In order to solve these problems, the present invention has a strong and broad antibacterial and antifungal spectrum in a cleaning composition comprising an antifungal agent and an antibacterial agent, particularly a cleaning composition intended to be used as a medicine, quasi-drug or cosmetics. It is stable, excellent in use, excellent in cleansing power, low in skin irritation, and can be used to prevent itching and deodorization of the scalp and body, and to prevent infectious diseases caused by resident bacteria or passing bacteria. It is an object to provide a composition.

본 발명자는 항진균제와 항세균제를 배합한 세정용 조성에 관하여 예의연구를 수행한 결과, 아졸계 항진균제와 항세균제를 배합한 세정용 조성물이 강력하고 넓은 항세균, 항진균 스펙트럼을 갖고, 제품자체가 안정하며, 사용감이 우수하고, 세정력이 우수하며, 피부자극 등의 유해현상을 나타내지 않고, 피부나 신체의 가려움의 방지나 방취효과를 얻을 수 있고, 상주균이나 통과균에 의한 감염증의 예방효과를 얻을 수 있는 등, 상기 과제의 적어도 하나를 해결할 수 있는 것을 발견하고, 본 발명을 완성하였다. As a result of earnestly researching the cleaning composition in which the antifungal agent and the antibacterial agent are combined, the present inventors have found that the cleaning composition containing the azole antifungal agent and the antibacterial agent has a strong and broad antibacterial and antifungal spectrum, and the product itself. It is stable, has a good feeling of use, has excellent cleaning power, does not show harmful effects such as skin irritation, prevents itching and deodorization of skin or body, and prevents infection by resident bacteria or passing bacteria. The inventors have found that at least one of the above problems can be solved, and thus the present invention has been completed.

이와 같은 본 발명에서는 아졸계 항진균제 및 항세균제가 배합된 의약품, 의약부외품 또는 화장품용의 세정용 조성물을 제공한다. Such a present invention provides a cleaning composition for medicines, quasi-drugs or cosmetics in which an azole antifungal agent and an antibacterial agent are blended.

상기 세정용 조성물에서, 상기 항진균제는 바람직하게는 미코나졸 및/또는 그의 염이다. 또한 상기 항세균제는 바람직하게는 트리클로산, 트리클로칼반 및 이소프로필메틸페놀에서 선택된 적어도 1종이다. In the cleaning composition, the antifungal agent is preferably myconazole and / or a salt thereof. In addition, the antibacterial agent is preferably at least one selected from triclosan, triclocarban and isopropylmethylphenol.

항진균제가 질산 미코나졸이고, 항세균제가 트리클로산인 세정용 조성물은 본 발명의 바람직한 1구체예이다. A cleaning composition wherein the antifungal agent is myconazole nitrate and the antibacterial agent triclosan is a preferred embodiment of the present invention.

본 발명의 세정용 조성물에서, 통상 항진균제의 배합량은 0.1∼2.0중량%이고, 항세균제의 배합량은 0.01∼1.5중량%이다. In the cleaning composition of the present invention, the compounding amount of the antifungal agent is usually 0.1 to 2.0% by weight, and the compounding amount of the antibacterial agent is 0.01 to 1.5% by weight.

본 발명의 세정용 조성물은 세정성분으로서 저자극성의 계면활성제를 포함할 수 있다. The cleaning composition of the present invention may include a hypoallergenic surfactant as a cleaning component.

본 발명의 세정용 조성물은 예컨대, 비누의 형태로 제공될 수 있다. The cleaning composition of the present invention may be provided, for example, in the form of a soap.

도 1은 본 발명의 비누의 세정효과를 대조 비누와 비교한 것으로, 실시에 5에서의 세균시험의 결과를 나타낸 그래프이다. 1 is a graph comparing the cleaning effect of the soap of the present invention with the control soap, showing the results of the bacterial test in Example 5.

도 2는 본 발명의 비누의 세정효과를 대조 비누와 비교한 것으로, 실시예 5에서의 진균시험의 결과를 나타낸 그래프이다. 2 is a graph comparing the cleaning effect of the soap of the present invention with the control soap, showing the results of the fungal test in Example 5.

이하 본 발명의 상세하게 설명한다. Hereinafter, the present invention will be described in detail.

본 발명은 의약품, 의약부외품 또는 화장용품의 항진균성·항세균성 세정용 조성물로, 넓은 항세균 및 항진균 스펙트럼을 갖는다. 본 발명의 세정용 조성물은 항진균제와 항세균제를 필수 배합성분으로 포함하고, 이 항진균제로서 아졸계 항진균제를 포함하는 것을 특징으로 한다. The present invention is an antifungal and antibacterial cleaning composition for pharmaceuticals, quasi-drugs or cosmetics, and has a broad antibacterial and antifungal spectrum. The cleaning composition of the present invention comprises an antifungal agent and an antibacterial agent as an essential ingredient, and the antifungal agent comprises an azole antifungal agent.

본 발명에서 아졸계 항진균제로서는 예컨대, 미코나졸, 클로트리마졸, 에코나졸, 티오코나졸, 옥시코나졸, 플루코나졸, 이트라코나졸, 케토코나졸, 클로코나졸, 네티코나졸, 이소코나졸, 술코나졸, 비포나졸 및 이들의 염 등을 들 수 있다. 염으로서는 질산염(nitrate), 염산염 등을 들 수있고, 바람직하게는 질산염이다. In the present invention, the azole antifungal agents include, for example, myconazole, clotrimazole, econazole, thioconazole, oxyconazole, fluconazole, itraconazole, ketoconazole, cloconazole, neticonazole, isoconazole, sulfonazole, and non-foam. Nazol, salts thereof, and the like. Examples of the salts include nitrates and hydrochlorides, and preferably nitrates.

본 발명에서는 이들의 2종 이상을 세정용 조성물중에 포함할 수 있다. In the present invention, two or more kinds thereof may be included in the cleaning composition.

이들중에서도 바람직하게는 미코나졸, 클로트리마졸, 에코나졸, 티오코나졸, 옥시코나졸, 술코나졸, 비포나졸 및 이들 염이고, 보다 바람직하게는 질산 미코나졸이다. Among these, preferably, they are myconazole, clotrimazole, econazol, thioconazole, oxyconazole, sulfonazole, biponazole and these salts, and more preferably myconazole nitrate.

본 명세서에서, 상기 미코나졸 및 질산 미코나졸은 하기 (I) 및 (II)로 나타낸 구조를 갖는 화합물을 의미한다:In the present specification, the myconazole and the nitrate myconazole mean a compound having the structures represented by the following (I) and (II):

Figure 112005010218809-pct00001
Figure 112005010218809-pct00002
Figure 112005010218809-pct00001
Figure 112005010218809-pct00002

(I) 미코나졸 (II) 질산 미코나졸(I) Myconazole (II) Myconazole Nitrate

상기 아졸계 항진균제는 시판품으로서 입수가능하다. The azole antifungal agent is available as a commercial item.

본 발명에 사용되는 항세균제는 세균에 대하여 증식억제작용을 갖는 것이면 특히 제한되는 것은 아니나, 디페닐에테르 화합물, 칼바닐리드 화합물 또는 페놀 화합물이 바람직하고, 구체적으로는 트리클로산, 트리클로칼반 및 이소프로필메틸페놀 등을 들 수 있다. 이중에서도 트리클로산이 바람직하다. The antibacterial agent used in the present invention is not particularly limited as long as it has a proliferation inhibitory effect on bacteria, but a diphenyl ether compound, a carbanilide compound, or a phenol compound is preferable, and specifically triclosan, triclokalban and isopropyl Methylphenol etc. are mentioned. Among them, triclosan is preferred.

이들 항세균제는 시판품으로서 입수가능하다. These antibacterial agents are available as a commercial item.

본 발명의 특히 바람직한 태양은 항진균제가 질산 미코나졸이고, 항세균제가 트리클로산인 조합이다. A particularly preferred aspect of the present invention is a combination wherein the antifungal agent is myconazole nitrate and the antibacterial agent is triclosan.

항진균제 및 항세균제의 조성물중의 배합량은 특히 한정되는 것은 아니지만, 통상 항진균제의 배합량은 0.1∼2.0중량%이고, 항세균제의 배합량은 0.01∼1.5중량%이다. 구체적으로, 항진균제가 질산 미코나졸인 경우에는, 그 배합량은 0.1∼1.0중량%가 바람직하고, 항세균제가 트리클로산의 경우에는, 그 배합량은 0.05∼1.0중량%가 바람직하다. Although the compounding quantity in the composition of an antifungal agent and an antibacterial agent is not specifically limited, Usually, the compounding quantity of an antifungal agent is 0.1 to 2.0 weight%, and the compounding quantity of an antibacterial agent is 0.01 to 1.5 weight%. Specifically, when the antifungal agent is myconazole nitrate, the compounding amount is preferably 0.1 to 1.0% by weight, and when the antibacterial agent is triclosan, the compounding amount is preferably 0.05 to 1.0% by weight.

항진균제와 항세균제와의 배합비는 특히 한정되지는 않지만, 항진균제:항세균제(중량:중량의 중량비)로 통상 1:5∼5:1, 바람직하게는 1:1∼5:1, 보다 바람직하게는 1:1∼2.5:1이고, 특히 바람직하게는 항진균제:항세균제=2:1∼2.5:1이다. 구체적으로 특히 바람직한 항진균제, 항세균제 및 이들 배합비의 조합은 항진균제가 질산 미코나졸이고, 항세균제가 트리클로산이고, 이들 배합비가 질산 미코나졸:트리클로산=2.5:1이다. The mixing ratio of the antifungal agent to the antibacterial agent is not particularly limited, but is usually 1: 5 to 5: 1, preferably 1: 1 to 5: 1, more preferably, as the antifungal agent: antibacterial agent (weight to weight ratio). Preferably 1: 1 to 2.5: 1, particularly preferably antifungal agent: antibacterial agent = 2: 1 to 2.5: 1. Particularly preferred antifungal agents, antibacterial agents and combinations of these combination ratios are those wherein the antifungal agent is myconazole nitrate, the antibacterial agent is triclosan, and the combination ratio is myconazole: triclosan = 2.5: 1.

본 발명에서는 세정용 조성물에 배합된 세정성분으로서는 항진균제 및 항세균제의 약효를 손상하지 않는 세정성분이면 특히 한정되는 것은 아니나, 음이온성 계면활성제를 포함하는 것이 바람직하다. 구체적으로는 알킬황산에스테르나트륨염등의 음이온성 계면활성제에 알킬디메틸암모늄베타인 등의 양이온성 계면활성제, 폴리옥시에틸렌알킬에테르 등의 비이온성 계면활성제 등을 적의 조합하여 사용할 수 있다. In the present invention, the cleaning component blended into the cleaning composition is not particularly limited as long as it is a cleaning component that does not impair the antifungal and antibacterial effects, but it is preferable to include an anionic surfactant. Specifically, cationic surfactants, such as alkyldimethylammonium betaine, nonionic surfactants, such as polyoxyethylene alkyl ether, etc. can be used suitably for anionic surfactants, such as alkyl sulfate ester sodium salt.

또한 이들 계면활성제는 저자극성인 것이 바람직하고, 저자극성의 음이온성 계면활성제로서는 모노알킬인산염, 아실글루타민산염, 아실메틸타우린산염, 코코일이세티온산염, 라우로일메틸-β-알라닌염 등을 들 수 있고, 저자극성의 양이온성 계면활성제로서는 베타인형 양이온성 계면활성제, 예컨대, 2-알킬-N-카르복시메틸-N-히드록시에틸이미다졸늄 베타인 등을 들 수 있다. 저자극성의 음이온성 계면활성제와 저자극성의 양이온성 계면활성제의 조합이 바람직하다. It is preferable that these surfactants are hypoallergenic, and as the hypoallergenic anionic surfactants, monoalkyl phosphates, acyl glutamate, acylmethyl taurate, cocoyl isethionate, lauroylmethyl-β-alanine salt, and the like Examples of the hypoallergenic cationic surfactant include betaine cationic surfactants such as 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazonium betaine. Combinations of hypoallergenic anionic surfactants and hypoallergenic cationic surfactants are preferred.

본 발명의 세정용 조성물에서는 또한 통상의 세정용 조성물에 사용될 수 있는 성분, 예컨대, 프로필렌글리콜, 글리셀린 등의 보습제, 양이온성 폴리머 등의 콘디셔닝 성분, 색소, 안료 등의 착색제, 메틸셀룰로스, 폴리에틸렌글리콜 등의 점도조절제, 구연산, 수산화칼륨 등의 pH조절제, 염화나트륨 등의 염류, 식물엑기스류, 방부제, 비타민제, 향료, 자외선흡수제, 항산화제, 물 등을 적의배합할 수 있다. The cleaning composition of the present invention may also be used in conventional cleaning compositions, for example, humectants such as propylene glycol and glycerin, conditioning components such as cationic polymers, colorants such as pigments and pigments, methylcellulose and polyethylene. Viscosity regulators such as glycol, pH regulators such as citric acid and potassium hydroxide, salts such as sodium chloride, plant extracts, preservatives, vitamins, fragrances, ultraviolet absorbers, antioxidants, water and the like can be suitably blended.

본 명세서에 있어서, 세정용 조성물로는 세정성분을 배합하고, 사용후에 흐르는 물등에 세척하여 사용하는 형태의 조성물을 의미한다. 이 형태는 특히 한정되는 것은 아니나, 비누(고형비누, 액체비누, 포상비노, 바디비누, 핸드비누 등), 클렌싱 거품, 샴프(두발용 샴프, 드라이샴프 등) 등을 들 수 있다. 이들 중에서도 비누가 바람직하고, 특히 액체비누, 바디비누가 바람직하다. In this specification, the composition for washing | cleaning means the composition of the form which mix | cleans a washing | cleaning component and wash | cleans in flowing water etc. after use. Although this form is not specifically limited, Soap (solid soap, liquid soap, foaming soap, body soap, hand soap, etc.), cleansing foam, shampoo (hair shampoo, dry shampoo, etc.) etc. are mentioned. Among these, soap is preferable and liquid soap and body soap are especially preferable.

이하에 본 발명의 세정용 조성물의 실시예를 나타내지만, 본 발명은 이들에 한정되는 것은 아니다. Although the Example of the cleaning composition of this invention is shown below, this invention is not limited to these.

(실시예 1) 질산 미코나졸 및 트리클로산의 인비트로에서의 항세균, 항진균작용Example 1 Antibacterial and Antifungal Activity of Nitric Acid Miconazole and Triclosan in Vitro

[대상균주]Target strain

<세균><Germ>

Staphylococcus aureus ATCC 29213 Staphylococcus aureus ATCC 29213

Escherichia coli ATCC 25922 Escherichia coli ATCC 25922

<진균><Fungus>

Candida albicans IFM 40213 Candida albicans IFM 40213

Trichophyton rubrum IFM 45626 Trichophyton rubrum IFM 45626

[MIC 값의 측정][Measurement of MIC value]

<세균><Germ>

(1) 뮤라힌톤II 한천배지(BBL)에서 35℃, 18∼20시간 배양후, 멸균생리식염수로서 McFarland No. 0.5로 조제하였다. 그후, 멸균생리식염수를 10배 희석하고, 공시균액으로 하였다. (1) After culturing at 35 ° C. for 18-20 hours in Murahinton II agar medium (BBL), McFarland No. 0.5 was prepared. Thereafter, sterile physiological saline was diluted 10-fold to prepare a test bacteria.

(2) 측정 약제는 DMSO로 용해하고, 미코나졸은 102,400㎍/mL(역가), 트리클로산은 409,600 ㎍/mL(역가)로 조제하였다. (2) The measurement drug was dissolved in DMSO, myconazole was prepared at 102,400 µg / mL (titer) and triclosan at 409,600 µg / mL (titer).

102,400㎍/mL(역가)로 조제된 미코나졸 약액은 또한 DMSO를 사용하여 2배 희석계열로 제조하고, 102,400∼50㎍/mL(역가)가 되도록 조제하였다. Myconazole chemicals prepared at 102,400 μg / mL (titer) were also prepared in 2-fold dilution series using DMSO and prepared to be 102,400-50 μg / mL (titer).

409,600 ㎍/mL(역가)로 조제한 트리클로산은 또한 DMSO를 사용하여 2배 희석 계열로 제조하고, 409,600∼6.00㎍/mL(역가)가 되도록 조제하였다. Triclosan prepared at 409,600 μg / mL (titer) was also prepared in 2-fold dilution series using DMSO and prepared to be 409,600 to 6.00 μg / mL (titer).

(3) 미코나졸은 1,024∼0.5㎍/mL, 트리클로산은 4.096∼0.06㎍/mL가 되도록 (2)에서 조제한 각 약제의 희석계열을 각각 양이온 조제한 Mueller-Hinton 브로스(CAMHB)에 첨가하였다(이때, 최종 DMSO 농도는 2% 이하가 되도록 하였다.)(3) The dilution series of each agent prepared in (2) was added to Mueller-Hinton broth (CAMHB) prepared by cation so that myconazole was 1,024 to 0.5 µg / mL and triclosan was 4.096 to 0.06 µg / mL (at this time, The final DMSO concentration was below 2%.)

(4) (3)에서 제조한 측정배지를 각각 100μL씩 분주하였다. 대조로서 약제 불함유 배지를 100μL씩 분주하였다.(4) 100 μL of the measuring medium prepared in (3) was dispensed. As a control, drug-free medium was dispensed in 100 μL increments.

(5) 접정균액을 각 웰에 5μL씩 접종하고, 대상으로서 사용한 약제 불함유 배지내의 균량을 측정하고, 접종균량을 구하였다. (5) 5 µL of the bacteriostatic solution was inoculated into each well, and the amount of bacteria in the drug-free medium used as a target was measured, and the amount of inoculated bacteria was determined.

(6) 대조로 사용한 약제 불함유 배지에서의 균의 발육을 확인한 후, 균의 발육이 육안적으로 확인되지 않은 웰의 최소의 약제농도를 MIC로 하였다. (6) After confirming the growth of bacteria in the drug-free medium used as a control, the minimum drug concentration in wells in which the growth of bacteria was not visually confirmed was set to MIC.

<진균><Fungus>

(1) C. albicans는 사브로덱스트로스 한천배지(BBL)에서 35℃, 24∼48시간 배양후, 멸균생리식염수로서 McFarland No. 0.5로 조제하였다. 0.165 mol/L MOPS를 포함하는 RPM1640 배지로 1000배로 희석하여, 공시균액(1∼5×103셀/mL)로 하였다. (1) C. albicans was incubated in Sabrodextrose agar medium (BBL) at 35 ° C. for 24 to 48 hours, followed by McFarland No. 0.5 was prepared. It was diluted 1000-fold with RPM1640 medium containing 0.165 mol / L MOPS, and it was set as the co-carrier liquid (1-5 * 10 <3> cell / mL).

T. rubrum은 개변 1/10 사브로·글루코스 한천사면배지에 27℃, 1∼2주간 배양후, 0.1% 트윈80가 멸균 생리식염수를 첨가한 분생자(condium)를 채취하고, 멸균 가제로 여과하였다. 분생자 현탁액은 또한 0.1% 트윈 80가 멸균 생리식염수로 희석하고, 혈구계산판을 이용하여 균수를 106셀/mL로 조제하여 공시균액으로 하였다. T. rubrum was incubated in a modified 1/10 Sabro Glucose agar medium for 27 ° C for 1 to 2 weeks, followed by collecting conidia containing 0.1% Tween 80 sterile saline solution and filtering with sterile gauze. It was. The conidia suspension was also diluted with 0.1% Tween 80 in sterile saline solution, and prepared by the hemocytometer at 10 6 cells / mL to prepare the test bacteria.

(2) 측정 약제는 DMSO로 용해하고, 미코나졸은 및 트리클로산 각각 12,800㎍ /mL(역가)로 조제하였다. 12,800㎍/mL(역가)로 조제된 미코나졸 및 트리클로산 약액은 또한 DMSO를 사용하여 2배 희석계열로 제조하고, 12,800∼60㎍/mL(역가)가 되도록 조정하였다. (2) The measurement agent was dissolved in DMSO, and myconazole was prepared at 12,800 µg / mL (titer), respectively, and triclosan. Myconazole and triclosan chemical solutions prepared at 12,800 μg / mL (titer) were also prepared in 2-fold dilution series using DMSO and adjusted to 12,800-60 μg / mL (titer).

(3) (2)에서 조제한 각 약제의 희석계열을 각각 0.165 mol/L MOPS를 포함한 RPMI 1640배지에 128∼0.06 ㎍/mL가 되도록 첨가하였다(이 때, 최종 DMSO 농도는 2% 이하가 되도록 하였다). (3) The dilution series of each drug prepared in (2) was added to the RPMI 1640 medium containing 0.165 mol / L MOPS so as to be 128 to 0.06 µg / mL (the final DMSO concentration was 2% or less). ).

(4) (3)에서 조제한 측정배지 100 μL에 대하여 (2)에서 조제한 균액 100 μL를 접종하고, C. albicans는 35℃에서 24∼48시간, T. rubrum은 27℃에서 1∼2주간 배양하였다. 단, 약제 불함유 배지에서의 균의 발육상태에 따라 배양시간은 적의 연장하였다. 대조로서 약제 불함유 배지를 100 μL씩 분주하였다. 4 (3) 100 μL inoculation of bacterial solution prepared in (2) with respect to the assay medium was adjusted to 100 μL in, C. albicans is 24-48 hours at 35 ℃, T. rubrum was cultured in 27 ℃ 1~2 jugan It was. However, depending on the growth state of the bacteria in the drug-free medium, the incubation time was prolonged. As a control, drug-free medium was dispensed in 100 μL increments.

(5) 대조로 사용된 약제 불함유 배지에서의 균의 발육을 확인한 후, 균의 발육이 육안적으로 확인되지 않은 웰의 최소의 약제농도를 MIC로 하였다. (5) After confirming the growth of the bacteria in the drug-free medium used as a control, the minimum drug concentration of the well in which the growth of the bacteria was not visually confirmed was MIC.

MIC 값(㎍/mL) 평가된 결과를 표 1중에 나타내었다. MIC values (μg / mL) The results of the evaluation are shown in Table 1.

표 1TABLE 1

질산 미코나졸Myconazole Nitrate 트리클로산Triclosan 세균Germ S. aureusS. aureus △△ ◎◎ E. coliE. coli ×× ○○ 진균
Fungus
C. abicansC. abicans ◎◎ △△ T. rubrumT. rubrum ○○ ××

식중, 평가 MIC 값(㎍/mL)In the formula, the evaluation MIC value (µg / mL)

◎ < 0.1           ◎ <0.1

○ 0.1∼1미만          ○ less than 0.1 ~ 1

△ 1∼10미만          △ less than 1 to 10

× 10≤          × 10≤

트리클로산은 세균에 대하여, 질산 미코나졸은 진균에 대하여 강력한 증식억제효과를 나타내었다. 양자를 혼합한 것으로 강력하거나 폭넓은 항진균, 항세균 스텍트럼을 얻을 수 있는 것을 알았다. Triclosan showed a potent antiproliferative effect against bacteria and nitrate myconazole against fungi. It was found that a mixture of both forms a strong or broad antifungal and antibacterial spectrum.

(실시예 2) 액체 비누의 조제예 (1)Example 2 Preparation of Liquid Soap (1)

본품 100g 중In 100 g of this article

트리클로산 0.30g Triclosan 0.30 g

질산 미코나졸 0.75gMyconazole Nitrate 0.75g

라우로일메틸-β-알라닌나트륨 12.00gLauroylmethyl-β-alanine sodium 12.00 g

2-알킬-N-카복시메틸-N-히드록시에틸이미다졸늄 베타인 12.00g2-alkyl-N-carboxymethyl-N-hydroxyethylimidazonium betaine 12.00 g

프로필렌글리콜 8.00gPropylene Glycol 8.00g

항산화제 적량Antioxidant Proper

pH 조절제 적량pH adjuster

정제수 적량Purified water

(실시예 3) 액체 비누의 안정성 시험Example 3 Stability Test of Liquid Soap

실시예 2에서 제조된 액체 비누는 조제 직후는 미황색 투명한 액체이고, 불용물 등은 확인되지 않았다. 따라서, 이 액체 바누를 온도 40℃, 상대습도 75%에서, 프라스틱 용기에서 6개월간 보존한 결과, 질산 미코나졸, 트리클로산의 잔재율은 어느것도 95% 이상(액체 크로마코그라프법을 이용한 상온에서 정량)이고, 또한 침전, 착색 등도 확인되지 않았다. The liquid soap prepared in Example 2 was a pale yellow transparent liquid immediately after preparation, and no insoluble matters were identified. Therefore, as a result of storing the liquid vane at a temperature of 40 ° C. and a relative humidity of 75% for 6 months in a plastic container, the residual ratios of myconate nitrate and triclosan were not less than 95% (quantified at room temperature using the liquid chromatograph method). ), And no precipitation or coloring was observed.

(실시예 4) 액체 비누의 사용 (1)Example 4 Use of Liquid Soap (1)

실시예 2에서 제조된 액체 비누를 통상의 방법에 따라 손세척 및 전신에 사용하였다. 세정시 및 세정후의 위화감, 피부의 강한자극감, 피부의 버석거림 등은 확인되지 않았고, 사용감이 우수하였다. The liquid soap prepared in Example 2 was used for hand washing and whole body according to a conventional method. Uncomfortable feeling during washing and after washing, strong irritation feeling of skin, stiffness of skin and the like were not confirmed, and the feeling of use was excellent.

본 액체 비누로 세정후에 한천배지에 손바닥 및 발바닥을 찍고(스탭프법), 통상의 방법에 따라 배양을 행하였다. 대조로서, 시판의 항세균 비누를 이용하여 동일한 시험을 실시하였다. 배양후에 검출된 세포수, 진균수는 본 발명의 액체 비누를 사용한 경우가 시판 항세균 비누를 사용한 경우에 비하여 명확하게 적었다. After washing with this liquid soap, palms and soles were taken on an agar medium (staff method), and cultured according to a conventional method. As a control, the same test was conducted using a commercially available antibacterial soap. The number of cells and fungi detected after the culturing was clearly less in the case of using the liquid soap of the present invention than in the case of using the commercially available antibacterial soap.

(실시예 5) 액체 비누의 사용(2)Example 5 Use of Liquid Soap (2)

[방법][Way]

실시예 2에서 제조한 액체 바누를 사용하여, 이하의 비교시험을 실시하였다. The following comparative tests were carried out using the liquid bain prepared in Example 2.

1. 세균시험1. Bacterial test

(1-1) 팜스탄프 배지(시판의 SCDLP 한천배지; 다이즈카제인 분해물, 레시틴 및 폴리솔베이트 80 함유)를 사용하여, 피험자(N=5)의 시험전의 균을 채취하였다. 시험 5시간 전부터 손세척을 금지하였다. (1-1) Bacteria before the test (N = 5) of the subject (N = 5) were harvested using a palmstane medium (commercially available SCDLP agar medium; containing diazcasein digest, lecithin and polysorbate 80). Hand washing was prohibited 5 hours before the test.

(1-2) 7%로 희석한 거품용기에 넣었던 실시예 2로 제조한 액체 비누(본 발명의 비누) 및 실시예 2의 조성으로부터 질산 미코나졸을 제외한 액체 비누(대조 비누)를 사용하여, 피험자의 우측 손바닥, 좌측 손바닥을 각각 일정시간 세정하였다. (1-2) Using a liquid soap prepared in Example 2 which was placed in a foam container diluted to 7% (soap of the present invention) and a liquid soap (control soap) excluding myconazole nitrate from the composition of Example 2, The right palm and the left palm of the subject were washed for a certain time, respectively.

세정은 본 발명 비누, 대조 비누의 각 담당자가 피험자에 대하여 브라인드하, 좌우 랜덤하게 피험자 전원의 손을 일정한 방법(2 푸쉬에서 5초간)으로 세정하는 벙법에 의해 실시하였다. The washing was performed by a method in which each person in charge of the soap and the control soap of the present invention was blinded with respect to the subject and washed the hands of all the subjects in a constant manner (from 2 pushes to 5 seconds) at random.

(1-3) 수도물(6L/분)으로 일정 기간(5초: 500mL)으로 세정제를 세척하였다. (1-3) The washing | cleaning agent was wash | cleaned in tap water (6L / min) for a fixed period (5 second: 500 mL).

(1-4) 양손을 드라이기(냉풍)으로 건조하여 다시 균을 채취하였다. (1-4) Both hands were dried with a dryer (cold air), and bacteria were again collected.

(1-5) 채취후 5시간 손을 세척하지 않고, 5시간후 다시 균을 채취하였다. (1-5) 5 hours after harvesting, hands were not washed, and 5 hours later, the bacteria were collected.

(1-6) 균을 채취한 배지를 24시간 35℃의 인큐베이타에서 배양하였다. (1-6) The culture medium was cultured in an incubator at 35 ° C for 24 hours.

(1-7) 검출된 배지의 사진을 촬영하여, 세균의 콜로니수를 측정하였다. (1-7) The photograph of the detected medium was taken, and the colony count of bacteria was measured.

2. 진균시험2. Fungal test

(2-1) 후톱클레스용 배지(박토아가 15g, 네오펩톤 10g, 포도당 20g, 시클로헥시미드 1000mg, 클로람페니콜 50mg, 황산 겐타마이신 100 mg, 증류수 1000mL)를 사용하여, 피검자(N=-5)의 시험전의 발의 균을 채취하였다. (2-1) Test subject (N = -5) using a medium for Hutopcles (15 g of bactoa, 10 g of neopeptone, 20 g of glucose, 1000 mg of cycloheximide, 50 mg of chloramphenicol, 100 mg of gentamicin sulfate, and 1000 mL of distilled water) The germs of the foot before the test were collected.

(2-2) 7%로 희석한 거품용기에 넣었던 본 발명 비누 및 대조 비누를 사용하여, 피험자의 좌측 발바닥, 우측발바닥을 각각 일정시간 세정하였다. (2-2) Using the soap of the present invention and the control soap, which were placed in a foam container diluted to 7%, the left sole and the right sole of the subject were washed for a predetermined time, respectively.

세정은 본 발명 비누, 대조 비누의 각 담당자가 피험자에 대하여 브라인드하, 좌우 랜덤하게 피험자 전원의 발을 일정한 방법(2 push에서 5초간)으로 세정하 는 벙법에 의해 실시하였다. The washing was performed by a method in which each person in charge of the soap and the control soap of the present invention was blinded to the subject and washed the feet of all the subjects in a constant manner (for 5 seconds in 2 pushes) at random.

(2-3) 수도물(6L/분)로 일정 기간(5초: 500mL)으로 세정제를 세척하였다. (2-3) The washing | cleaning agent was wash | cleaned in tap water (6L / min) for a fixed period (5 second: 500 mL).

(2-4) 양발을 드라이기(냉풍)으로 건조하여 다시 균을 채취하였다. (2-4) Both feet were dried with a dryer (cold air), and bacteria were again collected.

(2-5) 균을 채취한 배지를 7일∼14일 27℃의 인큐베이타에서 배양하였다. (2-5) The culture medium was cultured in an incubator at 27 ° C. for 7 to 14 days.

(2-6) 검출된 배지의 사진을 촬영하여, 진균의 콜로니수를 측정하였다. (2-6) The photograph of the detected medium was taken, and the number of colonies of fungi was measured.

[결과][result]

결과를 도 1(세균) 및 도 2(진균)에 나타내었다. The results are shown in FIGS. 1 (bacteria) and 2 (fungi).

도 1에서 나타낸 것과 같이, 본 발명 비누를 사용한 경우의 평균 세균 콜로니수(세정전을 100%로 하여 %로 표시)는 세정직후에는 현저하게 저하를 나타내었고, 세정 5시간후에 있어서도, 세정전보다 낮은 값이었다. 한편, 대조 비누는 세정직후에는 일시적으로 콜로니 수가 감소하였으나, 세정 5시간 후의 값은 세정전보다도 높은 값이었다. As shown in Fig. 1, the average bacterial colony number (expressed in% at 100% before washing) in the case of using the soap of the present invention was markedly lowered immediately after washing, and was lower than before washing even after 5 hours of washing. It was a value. On the other hand, the control soap temporarily decreased the number of colonies immediately after washing, but the value after 5 hours of washing was higher than before washing.

도 2에 나타낸 것과 같이, 본 발명 비누를 사용한 경우의 평균 진균 콜로니수(세정전을 100%로 하여 %로 표시)는 세정직후에는 현저한 저하를 나타내었다. 한편, 대조 비누는 세정직후에는 콜로니 수의 감소는 확인되지 않고, 오히려 세정전보다도 높은 값이었다. As shown in Fig. 2, the average fungal colony number (expressed in% at 100% before washing) in the case of using the soap of the present invention showed a significant decrease immediately after washing. On the other hand, the control soap did not show a decrease in the number of colonies immediately after washing, but rather was higher than before washing.

이하와 같이, 본 발명의 비누는 대조 비누에 비하여 항세균, 항진균 작용이 우수한 것을 확인하였다. As described below, the soap of the present invention was confirmed that the antibacterial, antifungal action is superior to the control soap.

(실시예 6) 질산 미코나졸 및 트리클로산의 혼합액의 인비트로에서의 항세균, 항진균작용Example 6 Antibacterial and Antifungal Activity of a Mixture of Nitrate-conazole and Triclosan in Vitro

[대상균주]Target strain

<세균><Germ>

Staphylococcus aureus ATCC 29213 Staphylococcus aureus ATCC 29213

Escherichia coli ATCC 25922 Escherichia coli ATCC 25922

<진균><Fungus>

Candida albicans IFM 40213 Candida albicans IFM 40213

Trichophyton rubrum IFM 45626 Trichophyton rubrum IFM 45626

[약제 배합비][Pharmaceutical Formulation Ratio]

(1) 질산 미코나졸:트리클로산 = 2.5:1(1) Myconazole nitrate: triclosan = 2.5: 1

(0.17107g:0.2863g)(0.17107g: 0.2863g)

(2) 질산 미코나졸:트리클로산 = 2:1(2) Myconazole nitrate: triclosan = 2: 1

(0.6634g:0.3340g)(0.6634g: 0.3340g)

(3) 질산 미코나졸:트리클로산 = 1:1(3) Myconazole nitrate: Triclosan = 1: 1

(0.4975g:0.5010g)(0.4975g: 0.5010g)

[약제 조제방법][Pharmaceutical preparation method]

(1) 질산 미코나졸 및 트리클로산을 상기 약제 배합비의 비율로 1g이 되도록 칭량하였다. (1) Myconazole nitrate and triclosan were weighed so as to be 1 g in the ratio of the above-mentioned drug formulation ratio.

(2) 이 1g을 디메틸설폭사이드(DMSO) 39.06mL에 용해하여, 25,600㎍/mL의 용액을 제조하였다. (2) This 1 g was dissolved in 39.06 mL of dimethyl sulfoxide (DMSO) to prepare a solution of 25,600 µg / mL.

(3) 25,600㎍/mL의 용액을 원액으로 하여, 이하의 시험에 사용하였다. (3) A 25,600 µg / mL solution was used as a stock solution and used for the following tests.

[MIC 값의 측정][Measurement of MIC value]

<세균><Germ>

(1) 뮤라힌톤II 한천배지(BBL)에서 35℃, 18시간 배양후, 멸균생리식염수로서 McFarland No. 0.5로 조제하였다. 그후, 멸균생리식염수를 10배 희석하고, 공시균액으로 하였다. (1) After culturing at 35 ° C. for 18 hours in Murahinton II agar medium (BBL), McFarland No. 0.5 was prepared. Thereafter, sterile physiological saline was diluted 10-fold to prepare a test bacteria.

(2) 상기 약제조제 방법으로 제조한 원액을 DMSO를 사용하여 2배 희석하고, 12,800㎍/mL로 저정후, 또한 DMSO를 사용하여 2배 희석계열을 제조하여, 12,800∼0.8㎍/mL(역가)가 되도록 조정하였다. (2) The stock solution prepared by the above pharmaceutical preparation method was diluted twice with DMSO, stored at 12,800 µg / mL, and then diluted twice with DMSO to prepare a 2-fold dilution series, and 12,800 to 0.8 µg / mL (titer). ).

(3) 128∼0.008㎍/mL가 되도록 (2)에서 제조한 약제의 희석 계열을 각각 양이온 조정한 Mueller-Hinton 브로스(CAMHB)에 첨가하였다(이때, 최종 DMSO 농도는 2% 이하가 되도록 하였다.)(3) A dilution series of the drug prepared in (2) was added to the cation-controlled Mueller-Hinton broth (CAMHB) so as to be 128 to 0.008 µg / mL (at this time, the final DMSO concentration was 2% or less). )

(4) (3)에서 제조한 측정배지를 각각 100μL씩 분주하였다. 대조로서 약제 불함유 배지를 100μL씩 분주하였다.(4) 100 μL of the measuring medium prepared in (3) was dispensed. As a control, drug-free medium was dispensed in 100 μL increments.

(5) (1)에서 조제한 균액 100 μL를 접종하고, C. albicans는 35℃, 48시간, T. rubrum은 27℃, 1주간 배양하였다. (5) 100 μL of the bacterial solution prepared in (1) was inoculated, and C. albicans was incubated at 35 ° C for 48 hours and T. rubrum at 27 ° C for 1 week.

(6) 대조로 사용한 약제 불함유 배지에서의 균의 발육을 확인한 후, 균의 발 육이 육안적으로 확인되지 않은 웰의 최소의 약제농도를 MIC로 하였다. (6) After confirming the growth of the bacteria in the drug-free medium used as a control, the minimum drug concentration in the well where the growth of the bacteria was not visually confirmed was MIC.

MIC 값(㎍/mL) 평가된 결과를 표 2중에 나타내었다. MIC values (µg / mL) The evaluated results are shown in Table 2.

표 2TABLE 2


질산 미코나졸/트리클로산Nitrate myconazole / triclosan 2.5:12.5: 1 2:12: 1 1:11: 1 세균Germ S. aureusS. aureus ◎◎ ◎◎ ○○ E. coliE. coli ○○ ○○ ○○ 진균Fungus C. abicansC. abicans ◎◎ ◎◎ ○○ T. rubrumT. rubrum ○○ ○○ ○○

식중, 평가 MIC 값(㎍/mL)In the formula, the evaluation MIC value (µg / mL)

◎ < 0.1          ◎ <0.1

○ 0.1∼1 미만         ○ 0.1 to less than 1

△ 1∼10 미만         △ 1 to less than 10

× 10≤         × 10≤

질산 미코나졸/트리클로산을 2.5:1∼1:1의 비율로 배합한 혼합액은 세균, 진균에 대하여 강력한 증식억제효과를 나타내었다. 양자를 혼합한 것으로 강력하고 폭넓은 항진균, 항세균 스텍트럼을 얻을 수 있는 것을 알았다. The mixed solution of nitrate myconazole / triclosan in a ratio of 2.5: 1 to 1: 1 showed strong antiproliferative effect against bacteria and fungi. It was found that a mixture of both forms a strong and broad antifungal and antibacterial spectrum.

(실시예 7) 액체비누의 조제예 (2)Example 7 Preparation of Liquid Soap (2)

본품 100g 중In 100 g of this article

트리클로산 0.30g Triclosan 0.30 g

질산 미코나졸 0.75gMyconazole Nitrate 0.75g

N-야자유 지방산 아실-L-글루타민산 칼륨 15.00gN-Palm Oil Fatty Acid Acyl-L-Glutamate Potassium 15.00g

2-알킬-N-카복시메틸-N-히드록시에틸이미다졸늄 베타인 10.00g2-alkyl-N-carboxymethyl-N-hydroxyethylimidazonium betaine 10.00 g

프로필렌글리콜 5.00gPropylene glycol 5.00g

항산화제 적량Antioxidant Proper

pH 조절제 적량pH adjuster

정제수 적량Purified water

(실시예 8) 액체비누의 조제예 (3)Example 8 Preparation of Liquid Soap (3)

본품 100g 중In 100 g of this article

트리클로산 0.50g Triclosan 0.50 g

질산 미코나졸 0.75gMyconazole Nitrate 0.75g

N-라우로일-L-글루타민산 칼륨 30.00gN-lauroyl-L-glutamic acid potassium 30.00 g

프로필렌 글리콜 3.00gPropylene Glycol 3.00g

프로필렌글리콜 5.00gPropylene glycol 5.00g

항산화제 적량Antioxidant Proper

pH 조절제 적량pH adjuster

정제수 적량Purified water

본 발명에서는 항진균제 및 항세균제가 배합된 신규한 의약품, 의약부외품 또는 화장용품의 본 발명의 세정용 조성물을 제공한다. 특히 진균제로서 아졸계 항진균제와 항세균제를 배합한 세정용 조성물은 강력하고 넓은 항세균, 항진균 스펙트럼을 갖고, 제품 자체가 안정하고, 사용감이 우수하고, 세정력이 우수하며, 피부자극 등의 유해성이 없고, 두피나 신체의 가려움의 방지나 방취효과를 얻을 수 있고, 상주균이나 통과균에 의한 감염증의 예방효과를 얻을 수 있는 등의 이들중 적어도 하나의 우수한 특징을 갖는다. The present invention provides a cleaning composition of the present invention of a novel drug, quasi-drug or cosmetics containing an antifungal agent and an antibacterial agent. In particular, the cleaning composition containing azole antifungal agent and antibacterial agent as a fungicide has a strong and broad antibacterial and antifungal spectrum, and the product itself is stable, excellent in use, excellent in cleaning power, and harmful to skin. At least one of them is excellent in preventing scalp and body itch, deodorizing effect, and preventing infectious diseases caused by resident bacteria and passing bacteria.

Claims (9)

미코나졸 또는 그의 염인 항진균제; 및 트리클로산, 트리클로칼반 및 이소프로필메틸페놀로부터 선택되는 적어도 1종의 항세균제가 배합된 세정용 조성물. Antifungal agents that are myconazole or salts thereof; And at least one antibacterial agent selected from triclosan, triclocarban and isopropylmethylphenol. 제1항에 있어서, 항진균제가 질산 미코나졸인 세정용 조성물.The cleaning composition according to claim 1, wherein the antifungal agent is myconazole nitrate. 제1항에 있어서, 항세균제가 트리클로산인 세정용 조성물.The cleaning composition according to claim 1, wherein the antibacterial agent is triclosan. 제1항에 있어서, 항진균제가 질산 미코나졸이고, 항세균제가 트리클로산인 세정용 조성물.The cleaning composition according to claim 1, wherein the antifungal agent is myconazole nitrate and the antibacterial agent is triclosan. 제1항에 있어서, 항진균제의 함유량이 0.1 내지 2.0중량%이고, 항세균제의 함유량이 0.01 내지 1.5중량%인 세정용 조성물. The cleaning composition according to claim 1, wherein the content of the antifungal agent is 0.1 to 2.0% by weight, and the content of the antibacterial agent is 0.01 to 1.5% by weight. 제1항 내지 제5항 중 어느 한 항에 있어서, 비누인 세정용 조성물.The cleaning composition according to any one of claims 1 to 5, which is a soap. 제1항에 있어서, 세정성분으로서 저자극성의 계면활성제를 포함하는 세정용 조성물.The cleaning composition according to claim 1, comprising a hypoallergenic surfactant as the cleaning component. 제7항에 있어서, 저자극성의 계면활성제가 저자극성의 음이온성 계면활성제인 세정용 조성물.The cleaning composition according to claim 7, wherein the hypoallergenic surfactant is a hypoallergenic anionic surfactant. 제8항에 있어서, 저자극성의 음이온성 계면활성제가 모노알킬인산염, 아실글루타민산염, 아실메틸타우린산염, 코코일이세티온산염, 라우로일메틸-β-알라닌염으로 이루어진 군에서 선택되는 1종 이상의 저자극성의 음이온성 계면활성제인 세정용 조성물.9. The hypoallergenic anionic surfactant according to claim 8, wherein the hypoallergenic anionic surfactant is selected from the group consisting of monoalkyl phosphates, acyl glutamate salts, acylmethyl taurate salts, cocoyl isethionate salts, lauroylmethyl-β-alanine salts. A cleaning composition, which is a species or more hypoallergenic anionic surfactant.
KR1020057003311A 2002-09-27 2003-09-26 Antifungal and antibacterial combination cleaning composition KR101045867B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002283651 2002-09-27
JPJP-P-2002-00283651 2002-09-27
PCT/JP2003/012325 WO2004028502A1 (en) 2002-09-27 2003-09-26 Cleansing composition containing antifungal agent and antibacterial agent

Publications (2)

Publication Number Publication Date
KR20050059141A KR20050059141A (en) 2005-06-17
KR101045867B1 true KR101045867B1 (en) 2011-07-01

Family

ID=32040564

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057003311A KR101045867B1 (en) 2002-09-27 2003-09-26 Antifungal and antibacterial combination cleaning composition

Country Status (5)

Country Link
JP (1) JPWO2004028502A1 (en)
KR (1) KR101045867B1 (en)
CN (1) CN100370965C (en)
AU (1) AU2003266643A1 (en)
WO (1) WO2004028502A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190104831A (en) 2018-03-02 2019-09-11 충북대학교 산학협력단 Pharmaceutical composition comprising miconazole for prevention or treatment of degenerative diseases of central nervous system
KR20200024190A (en) 2020-02-27 2020-03-06 충북대학교 산학협력단 Pharmaceutical composition comprising miconazole for prevention or treatment of degenerative diseases of central nervous system

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101413138B1 (en) 2005-05-16 2014-07-01 노바팜 리서치(오스트레일리아)피티와이리미티드 Method and composition for use in preparation of a patient for surgery
JP5615515B2 (en) * 2009-05-26 2014-10-29 持田製薬株式会社 Cleaning composition
CN102226135A (en) * 2011-05-12 2011-10-26 荆立民 Sterilizing/decontaminatimg/deodorizing shoe cleaning liquid and preparation method thereof
CN103857440B (en) 2011-06-22 2018-09-25 维奥姆生物科学有限公司 Antimycotic and antibacterium prodrug based on conjugate
CA2914583C (en) 2013-06-04 2019-06-18 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
JP6474963B2 (en) * 2014-03-04 2019-02-27 持田製薬株式会社 Cleaning composition
JP7030110B2 (en) * 2017-04-28 2022-03-04 持田製薬株式会社 Sheet preparation containing miconazole and / or miconazole nitrate
JP6837470B2 (en) * 2018-12-27 2021-03-03 持田製薬株式会社 Cleaning composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0680745A2 (en) 1994-05-05 1995-11-08 L'oreal Use of antifungals and or halogenated antibacterial agents for diminishing hair loss
JP2009176014A (en) 2008-01-24 2009-08-06 Oki Electric Ind Co Ltd Automatic transaction system and automatic transaction device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677983B1 (en) * 1991-06-24 1995-03-03 Oreal ALKYLTHIOPOLY (ETHYLIMIDAZOLIUM) COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS BIOCIDAL AGENTS.
US20020165168A1 (en) * 1995-12-16 2002-11-07 Joachim Bunger Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances
JP3793596B2 (en) * 1995-12-26 2006-07-05 大鵬薬品工業株式会社 Antifungal composition for external use
JP3603924B2 (en) * 1997-03-25 2004-12-22 ライオン株式会社 Fungicide composition
FR2798847B1 (en) * 1999-09-29 2001-11-23 Oreal COMPOSITION FOR THE TREATMENT OF DAIRY AND SCALP HAIR, BASED ON AN ANTI-DANDLING AGENT AND AN ACRYLIC TERPOLYMER
US7074392B1 (en) * 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
FR2826265B1 (en) * 2001-06-26 2005-02-18 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING AN ASSOCIATION BETWEEN AN ELASTIC INHIBITOR OF THE N-ACYLAMINOAMIDE FAMILY AND AT LEAST ONE ANTIFUNGAL AND / OR ANTIBACTERIAL AGENT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0680745A2 (en) 1994-05-05 1995-11-08 L'oreal Use of antifungals and or halogenated antibacterial agents for diminishing hair loss
JP2009176014A (en) 2008-01-24 2009-08-06 Oki Electric Ind Co Ltd Automatic transaction system and automatic transaction device

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190104831A (en) 2018-03-02 2019-09-11 충북대학교 산학협력단 Pharmaceutical composition comprising miconazole for prevention or treatment of degenerative diseases of central nervous system
KR20200024190A (en) 2020-02-27 2020-03-06 충북대학교 산학협력단 Pharmaceutical composition comprising miconazole for prevention or treatment of degenerative diseases of central nervous system

Also Published As

Publication number Publication date
JPWO2004028502A1 (en) 2006-01-19
CN1684662A (en) 2005-10-19
CN100370965C (en) 2008-02-27
AU2003266643A1 (en) 2004-04-19
KR20050059141A (en) 2005-06-17
WO2004028502A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2002350587B2 (en) Antimicrobial nanoemulsion compositions and methods
US8771731B2 (en) Antimicrobial nanoemulsion compositions and methods
US8232320B2 (en) Antimicrobial nanoemulsion compositions and methods
JPH11322591A (en) Antiseptic microbicide and composition for applying to human body
US20080057136A1 (en) Disinfecting Composition and Methods of Making and Using Same
US20090226384A1 (en) Antimicrobial composition containing triclosan and at least one functionalized hydrocarbon
US9693564B2 (en) Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate
EP2404502B1 (en) Compositions containing pyrrolidone carboxylic acid (pca) and metallic salts
US20240008486A1 (en) Preservation of personal care compositions
KR101045867B1 (en) Antifungal and antibacterial combination cleaning composition
CN111135160A (en) Foam wash-free antibacterial liquid for personal protection and preparation method thereof
US20150105472A1 (en) Antimicrobial composition
JP4255965B2 (en) Cleaning composition containing antifungal and antibacterial agents
JP2000319171A (en) Bactricidal skin lotion composition
KR102260163B1 (en) Antimicrobial Cosmetic Composition
US11324680B2 (en) Topical compositions
US20220168201A1 (en) Use of dianhydrohexitol for preserving cosmetic preparations
ZA200604768B (en) Disinfecting composition and methods of making and using same
MXPA06005233A (en) Disinfecting composition and methods of making and using same
KR20070042739A (en) Composition for preventing and treating of dandruff comprising vitamin b1 derivatives
GB2293765A (en) Disinfectant composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20140603

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20150601

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20160527

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20170601

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20180529

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20190530

Year of fee payment: 9